Media Coverage

Media Coverage

Read how Vistagen’s intention to revolutionize mental health medicine is causing a buzz in the media.

Thepharmaletter logo image
VistaGen out-licenses rights to anxiety disorder candidate in Asia territories
Read
MD Magazine logo image
DocTalk Podcast: The Psychological Damage of the COVID-19 Pandemic
Read
Taylor & Francis logo image
An interview with Shawn Singh: Chief Executive Officer and Director of VistaGen Therapeutics
Read
GENE Online logo image
VistaGen’s Antidepressant Nasal Spray Succeeds Phase 2a Trial
Read
Parkinson's News Today logo image
FDA Clears Way for Phase 2 Trial of AV-101 for Levodopa-Induced Dyskinesia
Read
Neurologylive logo image
Investigational Dyskinesia Treatment Gets FDA Green Light
Read
Clinical Trials Arena logo image
VistaGen to study dyskinesia drug in Phase II Parkinson’s trial
Read
HCP Live network logo image
FDA Clears Study to Test New Drug to Treat Dyskinesia for Parkinson Patients
Read
Pshyciatry Advisor logo image
Intranasal Therapy Fast-Tracked for Social Anxiety Disorder
Read